EuroBiotech: More Articles of Note


> Oxurion’s THR-317 failed to improve vision in patients with diabetic macular edema in a phase 2a trial. The antibody against placental growth factor was no better than placebo in the overall population, but Oxurion highlighted a “certain improvement” in pre-specified subgroups. Statement  

> Abivax enrolled the first patient in its ulcerative colitis phase 2b trial. Top-line data are due next year. Release 

> Redx Pharma finished dosing the first cohort of patients in a phase 1/2 trial of oral porcupine inhibitor RXC004. Enrollment of the second cohort, which will receive a higher dose, is underway. Statement 


Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

> Motif Bio revealed the National Institutes of Health is funding preclinical testing of iclaprim against Listeria monocytogenes. Release

> Scancell withdrew an IND filing for SCIB1. The FDA held up the start of the trial by requesting extra information, leading Scancell to drop the IND so enrollment in the U.K. can begin. Statement 

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.